Lexaria Bioscience Corp.

LEXX • Biotechnology

Strong market move

LEXX+14.85%

vs. previous close $12.32

$14.15

▲ +1.83 (+14.85%)

Current price

EarningsLatest report: Feb 28, 2026

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$345.88M

Growth

-6.0%

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.04Healthy liquidity · 2.32Negative growth trendWeak profitability

Financial data as of: Feb 28, 2026, 12:00 AM UTCLast earnings update: Apr 13, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$14.15

Change14.85%

Shares Out24.44M

Market Cap$345.88M

Enterprise Value$340.61M

52W Range0.46 - 1.55

Beta0.34

P/E-36.29

P/S939.89

P/B52.39

P/FCF-36.72

EV/Sales925.57

Price$14.15

Change14.85%

Shares Out24.44M

Market Cap$345.88M

Enterprise Value$340.61M

52W Range0.46 - 1.55

Beta0.34

P/E-36.29

P/S939.89

P/B52.39

P/FCF-36.72

EV/Sales925.57

EV/EBITDA-36.33

EV/FCF-36.16

Earnings Yield-2.76%

FCF Yield-2.72%

Dividend Yield0.00%

Gross Margin99.61%

Oper. Margin-16.83%

Profit Margin-16.86%

Debt/Eq0.04

Current Ratio2.32

Quick Ratio2.32

Revenue 5Y-5.99%

Target$1.50

Target Upside-89.40%

Target Median$1.50

Target Range1.50 - 1.50

Volume50.64K

Avg Volume121.12K

EPS Surprise0.04

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

40/100

Why this score▼

Manageable debt level · 0.04Healthy liquidity · 2.32Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

LEXX

Analyst sentiment

Based on 2 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Price Target

2026-07-15

Low

$1.50

Mean

$1.50

Median

$1.50

High

$1.50

Company Overview

IPO: 1/12/2021

Industry: Biotechnology

P/B i: 52.39

Debt / Equity i: 0.04

Operating Margin: -1683.01%

Net Margin: -1686.00%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.04

Current Ratio: 2.32

Quick Ratio: 2.32

Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 1 high-volume insider sell detected

BUNKA CHRISTOPHER

Transaction: 03/17/2026

SELL

Change

-100,000

Price

Not reported

Filing

03/18/2026

Type

SELL

BUNKA CHRISTOPHER

Transaction: 07/30/2025

BUY

Change

+11,900

Price

$0.91

Filing

07/30/2025

Type

BUY

CHRISTOPHER RICHARD

Transaction: 07/29/2025

BUY

Change

+15,000

Price

$0.91

Filing

07/30/2025

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
BUNKA CHRISTOPHER	SELL	-100,000	Not reported	03/17/2026	03/18/2026
BUNKA CHRISTOPHER	BUY	+11,900	$0.91	07/30/2025	07/30/2025
CHRISTOPHER RICHARD	BUY	+15,000	$0.91	07/29/2025	07/30/2025
Carle Vanessa	BUY	+750	$0.91	07/29/2025	07/30/2025
DOCHERTY JOHN MARTIN	BUY	+5,376	$0.93	07/29/2025	07/30/2025
McKechnie William Edward	BUY	+5,000	$0.91	07/29/2025	07/30/2025
BUNKA CHRISTOPHER	BUY	+15,600	$0.92	07/29/2025	07/30/2025
REESE ALBERT L JR	BUY	+11,000	$1.04	05/15/2025	05/16/2025
Baxter Nicholas W	BUY	+11,000	$1.04	05/15/2025	05/16/2025
Bhullar Baljinder	BUY	+11,000	$1.04	05/15/2025	05/16/2025
Shankman Michael Elliot	BUY	+50,000	$1.04	05/15/2025	05/16/2025
DOCHERTY JOHN MARTIN	BUY	+150,000	$1.04	05/15/2025	05/16/2025
Carle Vanessa	BUY	+15,000	$1.04	05/15/2025	05/16/2025
BUNKA CHRISTOPHER	BUY	+11,000	$1.04	05/15/2025	05/16/2025
CHRISTOPHER RICHARD	BUY	+150,000	$1.04	05/15/2025	05/16/2025
Bhullar Baljinder	OTHER	0	Not reported	01/14/2025	01/16/2025
BUNKA CHRISTOPHER	BUY	+100,000	Not reported	01/07/2025	01/10/2025
CHRISTOPHER RICHARD	BUY	+27,172	$2.47	12/03/2024	12/03/2024
CHRISTOPHER RICHARD	BUY	+22,828	$2.24	12/02/2024	12/03/2024
Shankman Michael Elliot	OTHER	+50,000	$3.17	02/28/2025	10/02/2024

About the Company

Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.

Source - link

Peers

ALLR BCTX CASI CING CLSD CRIS ENTO HOTH LIXT PCSA

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kelowna, British Columbia – September 4, 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14 th through September 16 th, 2026 in New York City. Richard Christopher, CEO of Lexaria Bioscience Corp, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. The presentation will be available to view online using this link.

TheNewswire

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate Kelowna, British Columbia – September 1, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.

TheNewswire

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.

Accesswire

DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs KELOWNA, BC / ACCESS Newswire / August 24, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that blood plasma pharmacokinetic ("PK") bioanalysis testing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2, the "Study"). The Study examined oral delivery of 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs, amycretin and retatrutide, in a total of 18 different study arms in dogs following formulation and processing using Lexaria's patented DehydraTECHTM ("DHT") drug delivery enabling platform technology formulated in oral tablet and capsule formats.

Accesswire

Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know

Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd. Here's what investors need to know.

Benzinga

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-04-13	-0.1	-0.06	0.04
2026-01-13	-0.13	-0.07	0.06
2025-11-26	-0.16	-0.13	0.03
2025-07-14	-0.15	-0.21	-0.06
2025-04-14	-0.16	-0.15	0.01
2025-01-10	-0.12	-0.16	-0.04
2024-11-26	-0.11	-0.15	-0.04
2024-07-12	-0.1	-0.13	-0.03
2024-04-09	-0.1	-0.06	0.04
2024-01-12	-0.11	-0.13	-0.02
2023-11-21	-0.17	-0.12	0.05
2023-07-14	-0.25	-0.37	-0.12